Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Theravance Bio Ord (TBPH)
Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 470,093
  • Shares Outstanding, K 49,798
  • Annual Sales, $ 51,350 K
  • Annual Income, $ 872,130 K
  • 60-Month Beta 0.36
  • Price/Sales 8.21
  • Price/Cash Flow N/A
  • Price/Book 2.02
Trade TBPH with:

Options Overview Details

View History
  • Implied Volatility 53.26% ( +18.83%)
  • Historical Volatility 38.00%
  • IV Percentile 80%
  • IV Rank 35.36%
  • IV High 115.94% on 02/26/24
  • IV Low 18.96% on 09/01/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 1,315
  • Open Int (30-Day) 1,248

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -0.32
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.21 +14.98%
on 02/08/24
10.11 -6.63%
on 02/27/24
+0.28 (+3.06%)
since 02/01/24
3-Month
8.21 +14.98%
on 02/08/24
11.71 -19.39%
on 01/04/24
-1.21 (-11.36%)
since 12/01/23
52-Week
8.21 +14.98%
on 02/08/24
12.03 -21.53%
on 04/17/23
-0.60 (-5.98%)
since 03/01/23

Most Recent Stories

More News
Theravance Bio: Q4 Earnings Snapshot

Theravance Bio: Q4 Earnings Snapshot

TBPH : 9.44 (-0.32%)
Theravance Bio: Q3 Earnings Snapshot

Theravance Bio: Q3 Earnings Snapshot

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Report Third Quarter 2023 Financial Results on November 7, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2023 financial results and provide a business update after market close...

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Participate in an Upcoming Investor Conference

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference...

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic...

TBPH : 9.44 (-0.32%)
Theravance Bio: Q2 Earnings Snapshot

Theravance Bio: Q2 Earnings Snapshot

TBPH : 9.44 (-0.32%)
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 Q2 2023 YUPELRI total retail TRx and new to product TRx...

TBPH : 9.44 (-0.32%)
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023

/PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market...

TBPH : 9.44 (-0.32%)
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy

/PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration...

TBPH : 9.44 (-0.32%)
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

TBPH : 9.44 (-0.32%)
ITRM : 1.3000 (+4.84%)
LRMR : 11.35 (-1.30%)
VTRS : 12.59 (+1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Theravance Biopharma is a biopharmaceutical company primarily focused on discovering, developing and commercializing respiratory medicines. The company was formed following the split of the erstwhile Theravance into two listed companies in June 2014 - Innoviva, Inc. (then Theravance, Inc.) and Theravance.'...

See More

Key Turning Points

3rd Resistance Point 9.94
2nd Resistance Point 9.79
1st Resistance Point 9.62
Last Price 9.44
1st Support Level 9.30
2nd Support Level 9.15
3rd Support Level 8.98

See More

52-Week High 12.03
Fibonacci 61.8% 10.57
Fibonacci 50% 10.12
Fibonacci 38.2% 9.67
Last Price 9.44
52-Week Low 8.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar